Core Viewpoint - The high-quality performance of the Gaozhou Puppet Show, a national intangible cultural heritage, attracted a large audience at the event held in Guangzhou's Baiyun Mountain, showcasing the cultural richness and innovative spirit of the art form [1][5][19]. Group 1: Event Overview - On May 1, the Gaozhou Puppet Show performed "Xian Tai Lian Bing" at Baiyun Mountain, drawing significant attention from citizens and tourists [2][8]. - The event featured various performances, including "Nezha," "Retro Disco," and "Tang Gu La Feng Bao," which combined traditional puppet techniques with contemporary themes to engage younger audiences [16][18]. Group 2: Cultural Significance - Gaozhou Puppet Show, also known as "Gui Zi Xi," was recognized as a national intangible cultural heritage in 2006, highlighting its historical and cultural importance [20][21]. - The show has a strong local support system, with 2 national-level inheritors, 4 city-level, and 5 county-level inheritors, along with a puppet association comprising over 500 members and 132 puppet troupes [21][22]. Group 3: Audience Engagement - The audience actively participated in the event, capturing performances on their phones and engaging in interactive games, which contributed to the lively atmosphere [4][29]. - The event also included a promotional segment for Gaozhou's agricultural and cultural tourism products, with over 40 enterprises showcasing more than 100 products [31][32]. Group 4: Agricultural Promotion - Gaozhou, known as the "Hometown of Lychee," produces over 500,000 tons of lychee annually, accounting for one-fourth of China's total lychee production [36]. - The city launched customized lychee activities targeting various groups, enhancing community engagement and promoting local agricultural products [38][43].

本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 证券代码：600332 证券简称：白云山 公告编号：2025－035 广州白云山医药集团股份有限公司 第九届董事会第二十三次会议决议公告 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第二十三次 会议（"会议"）通知于 2025 年 4 月 15 日以书面及电邮方式发出，于 2025 年 4 月 29 日以通讯表决的方式召开。本次会议应参加表决董事 8 人，实际参加表决 董事 8 人，有效表决权人数 8 人。会议的召集、召开符合《公司法》及《公司 章程》的规定。 经董事审议、表决，会议审议通过如下议案： 一、本公司 2025 年第一季度报告 二、关于续聘大信会计师事务所（特殊普通合伙）为本公司 2025 年年度财 务审计机构的议案（有关内容详见本公司日期为 2025 年 4 月 29 日、编号为 20 25-036 的公告） 表决结果：同意票 8 票、反对票 0 票、弃权票 0 票，审议通过本议案。 本议案已经本公司董事会审核委员会 2025 年第 2 次会议审议通过。 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 22,473,408,393, a decrease of 2.06% compared to CNY 22,946,211,892 in the same period last year[4]. - Net profit attributable to shareholders was CNY 1,821,313,254, down 6.99% from CNY 1,958,118,124 year-on-year[4]. - Basic and diluted earnings per share were both CNY 1.120, a decrease of 6.99% from CNY 1.204 in the same period last year[4]. - Total operating revenue for Q1 2025 was CNY 22,473,408,392.77, a decrease of 2.06% from CNY 22,946,211,891.84 in Q1 2024[20]. - Net profit for Q1 2025 was CNY 1,857,449,310.65, a decrease of 8.54% compared to CNY 2,031,724,927.91 in Q1 2024[21]. - The company’s total comprehensive income for Q1 2025 was CNY 1,850,877,925.86, down from CNY 2,033,231,749.61 in Q1 2024[22]. Cash Flow - The net cash flow from operating activities was negative CNY 3,897,258,025, representing a decline of 24.19% compared to the previous year[4]. - Cash inflow from operating activities in Q1 2025 was CNY 15,913,593,244.88, compared to CNY 16,789,987,378.48 in Q1 2024[23]. - The net cash flow from operating activities was negative at (3,897,258,025.12), compared to (3,138,186,616.77) in the previous period, indicating a decline in operational cash generation[24]. - The total cash and cash equivalents at the end of the period decreased to 12,699,134,891.11 from 18,344,448,005.36, reflecting a significant reduction in liquidity[25]. - The company reported a total cash outflow from operating activities of 19,810,851,270.00, slightly down from 19,928,173,995.25, suggesting stable operational expenses[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 80,047,799,450, a decrease of 2.00% from CNY 81,683,611,521 at the end of the previous year[6]. - The company's current assets totaled ¥55,673,034,339.05, down from ¥57,762,228,309.37, indicating a decrease of about 3.63%[16]. - Total liabilities decreased to ¥40,408,879,746.27 from ¥43,913,975,774.25, a decline of about 8.5%[17]. - The non-current liabilities decreased to ¥4,299,969,166.95 from ¥4,998,286,418.68, indicating a reduction of about 14.0%[17]. Shareholder Information - The equity attributable to shareholders increased by 5.05% to CNY 37,719,037,765 from CNY 35,904,527,869 at the end of the previous year[6]. - The total number of ordinary shareholders at the end of the reporting period was 93,536[12]. - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[12]. Operational Efficiency - The weighted average return on net assets was 4.95%, down 0.5 percentage points from 5.45% at the end of the previous year[6]. - Research and development expenses for Q1 2025 were CNY 143,713,072.16, a decrease of 22.73% from CNY 186,139,000.55 in Q1 2024[20]. - The company paid 1,669,345,024.24 in cash to employees, a decrease from 1,744,322,516.63, indicating cost management efforts[24]. Investment Performance - The company reported an investment income of CNY 131,136,370.42, up from CNY 102,119,649.77 in Q1 2024[20]. - Cash inflow from investment income was 63,221,276.30, up from 32,695,487.98, reflecting improved investment performance[24]. Other Information - The company has not reported any new strategies or product developments during this period[14]. - The impact of exchange rate changes on cash and cash equivalents was positive at 6,328,259.74, compared to 2,432,159.43 previously, indicating some currency gains[24].

证券代码：600332 证券简称：白云山 公告编号：2025－036 广州白云山医药集团股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2、人员信息 首席合伙人为谢泽敏。截至 2024 年 12 月 31 日，大信从业人员总数 3,957 人，其中合伙人 175 人，注册会计师 1,031 人。注册会计师中，超 过 500 人签署过证券服务业务审计报告。 3、业务规模 2023 年度业务收入 15.89 亿元（人民币，下同），为超过 10,000 家 公司提供服务。业务收入中，审计业务收入 13.80 亿元、证券业务收入 4.50 亿元。2023 年上市公司年报审计客户 204 家（含 H 股），平均资产 额 146.53 亿元，收费总额 2.41 亿元。主要分布于制造业、信息传输、软 件和信息技术服务业，电力、热力、燃气及水生产和供应业，科学研究和 1 技术服务业，水利、环境和公共设施管理业。广州白云山医药集团股份有 限公司（"白云山"、"本公司"）同行业上市公司审计 ...

证券代码：600332 证券简称：白云山 公告编号：2025-038 广州白云山医药集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 控股子公司广州白云山天心制药股份有限公司（以下简称"天心药业"） 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》， 注射用头孢噻肟钠（0.5g、1.0g）已通过仿制药质量和疗效一致性评 价。现将有关情况公告如下： 药品注册标准编号：YBH09572025 上市许可持有人名称：（1）名称：广州白云山天心制药股份有限 公司；（2）地址：广州市海珠区滨江东路808号 生产企业：（1）名称：广州白云山天心制药股份有限公司；（2） 一、药品的基本情况 药品通用名称：注射用头孢噻肟钠 通知书编号：2025B01842、2025B01843 受理号：CYHB2350967、CYHB2350968 剂型：注射剂 规格：0.5g（按C16H17N5O7S2计）、1.0g（按C16H17 ...

1 证券代码：600332 证券简称：白云山 公告编号：2025－034 广州白云山医药集团股份有限公司 关于控股子公司广州医药股份有限公司 获准在新三板挂牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、基本情况概述 广州白云山医药集团股份有限公司（"本公司"）分别于 2023 年 12 月 19 日、2024 年 1 月 26 日召开的第九届董事会第六次会议和 2024 年第 一次临时股东大会审议通过了《关于控股子公司拟申请在新三板挂牌的议 案》，同意控股子公司广州医药股份有限公司（"广州医药"）申请在全国 中小企业股份转让系统（新三板）挂牌（"本次挂牌"）。2024 年 6 月 17 日，广州医药获得全国中小企业股份转让系统有限责任公司（"全国股转 公司"）出具的《受理通知书》，对其报送的新三板挂牌申请材料予以受 理。有关内容详见本公司日期为 2023 年 12 月 19 日、2024 年 1 月 26 日 及 2024 年 6 月 17 日的相关公告。 二、本次挂牌的进展情况 广州医药于 2025 年 4 ...

1 附：董事候选人简历 一、程洪进先生 本事项尚需提交本公司 2024 年年度股东大会审议并采用累积投票方 式表决。 特此公告。 广州白云山医药集团股份有限公司 关于补选董事的公告 广州白云山医药集团股份有限公司董事会 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 29 日 证券代码：600332 证券简称：白云山 公告编号：2025－037 广州白云山医药集团股份有限公司（以下简称"本公司"）于 2025 年 4 月 29 日召开了本公司第九届董事会第二十三次会议，审议通过了《关 于提名程洪进先生为本公司第九届董事会执行董事候选人并建议其 2025 年度薪酬的议案》和《关于提名唐和平先生为本公司第九届董事会执行董 事候选人并建议其 2025 年度薪酬的议案》。根据《公司法》等法律法规 和《公司章程》的规定，经本公司控股股东广州医药集团有限公司（"广 药集团"）推荐，本公司第九届董事会提名与薪酬委员会 2025 年第 2 次 会议对上述董事候选人的个人简历、任职资格等进行了审查，本公司董事 会同意提名程 ...

Financial Performance - The company's operating revenue for the first quarter was RMB 22,473,408,393, a decrease of 2.06% compared to RMB 22,946,211,892 in the same period last year[8]. - Net profit attributable to shareholders was RMB 1,821,313,254, reflecting a decline of 6.99% from RMB 1,958,118,124 year-on-year[8]. - Basic and diluted earnings per share both stood at RMB 1.120, down 6.99% from RMB 1.204 in the same period last year[8]. - Operating profit for Q1 2025 was RMB 2,227,367,213.28, down 9.15% from RMB 2,452,250,842.21 in Q1 2024[29]. - Net profit for Q1 2025 was RMB 1,857,449,310.65, down 8.54% from RMB 2,031,724,927.91 in Q1 2024[29]. - Earnings per share for Q1 2025 was RMB 1.120, compared to RMB 1.204 in Q1 2024, reflecting a decrease of 6.98%[31]. - Other comprehensive income after tax for Q1 2025 was RMB (6,571,384.79), compared to RMB 1,506,821.70 in Q1 2024, indicating a significant decline[29]. Cash Flow - The net cash flow from operating activities was negative at RMB (3,897,258,025), worsening by 24.19% compared to RMB (3,138,186,617) in the previous year[8]. - In Q1 2025, the cash inflow from operating activities was RMB 15.91 billion, a decrease of 5.2% compared to RMB 16.79 billion in Q1 2024[32]. - The net cash outflow from operating activities was RMB (3.90) billion, worsening from RMB (3.14) billion in the same period last year[32]. - Cash inflow from investment activities totaled RMB 727.84 million, significantly higher than RMB 75.78 million in Q1 2024[33]. - The net cash outflow from investment activities was RMB (738.65) million, compared to RMB (282.99) million in Q1 2024[33]. - Cash inflow from financing activities was RMB 4.31 billion, down from RMB 6.27 billion in Q1 2024[33]. - The net cash inflow from financing activities was RMB 1.03 billion, a decrease from RMB 1.94 billion in the previous year[33]. - The net increase in cash and cash equivalents for Q1 2025 was RMB (3.60) billion, compared to RMB (1.48) billion in Q1 2024[34]. - The ending balance of cash and cash equivalents was RMB 12.70 billion, down from RMB 18.34 billion at the end of Q1 2024[34]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 80,047,799,450, a decrease of 2.00% from RMB 81,683,611,521 at the end of the previous year[8]. - Total current assets amounted to RMB 55.67 billion, a decrease of 3.6% from RMB 57.76 billion as of December 31, 2024[24]. - Total non-current assets reached RMB 24.37 billion, an increase of 1.9% from RMB 23.92 billion[25]. - Total liabilities decreased to RMB 40.41 billion, down 8.6% from RMB 43.91 billion[26]. - Short-term borrowings slightly decreased to RMB 9.01 billion from RMB 9.12 billion[26]. - The company reported a total asset value of RMB 80.05 billion, a decrease from RMB 81.68 billion[25]. - The total liabilities and equity as of March 31, 2025, were RMB 80,047,799,450.33, compared to RMB 81,683,611,520.64 at the end of 2024, showing a decrease of 2.01%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 93,536[18]. - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[19]. - Shareholders' equity attributable to the parent company increased by 5.05% to RMB 37,719,037,765 from RMB 35,904,527,869 at the end of the previous year[8]. - The total equity attributable to shareholders increased to RMB 37,719,037,764.76 as of March 31, 2025, up from RMB 35,904,527,868.59 at the end of 2024, representing a growth of 5.03%[27]. - Minority interest increased to RMB 1,919,881,939.30 as of March 31, 2025, from RMB 1,865,107,877.80 at the end of 2024, reflecting a growth of 2.91%[27]. Operational Insights - The company reported a non-operating income of RMB 41,380,031 from government subsidies during the period[13]. - The company has not reported any changes in major shareholders or their participation in financing activities[22]. - There are no significant reminders or additional important information regarding the company's operational status during the reporting period[23]. - Research and development expenses for Q1 2025 were RMB 143,713,072.16, a decrease of 22.73% compared to RMB 186,139,000.55 in Q1 2024[28]. - Accounts receivable increased to RMB 17.65 billion, up 11.7% from RMB 15.73 billion in the previous period[24]. - Inventory decreased to RMB 10.82 billion, down 15.5% from RMB 12.81 billion as of December 31, 2024[24]. - The impact of exchange rate changes on cash and cash equivalents was an increase of RMB 6.33 million, compared to RMB 2.43 million in Q1 2024[34].

Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector experienced a decline of 0.81%, ranking among the top declines in the concept sector [1] - Within the Artemisinin concept sector, major companies such as Kunming Pharmaceutical Group, New Harmony, and Rundu Co., Ltd. saw significant declines, while companies like Baihua Pharmaceutical, China Resources Sanjiu, and Zhejiang Medicine recorded gains of 1.21%, 0.75%, and 0.75% respectively [1] Group 2 - The financial data shows that the Artemisinin concept sector had a net outflow of 96 million yuan, with eight stocks experiencing net outflows, led by Kunming Pharmaceutical Group with a net outflow of 62.05 million yuan [2] - Other companies with notable net outflows include Rundu Co., Ltd. with 11.84 million yuan, Fosun Pharmaceutical with 9.02 million yuan, and Zhejiang Medicine with 6.48 million yuan [2] - Conversely, the stocks with the highest net inflows included Baihua Pharmaceutical and New Harmony, with net inflows of 6.07 million yuan and 1.19 million yuan respectively [2]

广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山明兴制药有限公司（以下简称"明兴药业"）收 到广东省药品监督管理局核准签发的《药品生产许可证》，同意明 兴药业核减生产范围、生产车间和生产线。现将相关情况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山明兴制药有限公司 证券代码：600332 证券简称：白云山 公告编号：2025－033 许可证编号：粤 20160012 分类码：AhzxBzCzDhz 注册地址：广州市海珠区工业大道北 48 号 发证机关：广东省药品监督管理局 有效期至：2025 年 11 月 22 日 生产地址和生产范围： 1、广州市黄埔区尖塔山路 1 号，原料药［门冬酰胺酶（欧文）］； 2、广州市海珠区工业大道北 48 号，片剂，硬胶囊剂，颗粒剂，合剂， 乳剂，小容量注射剂（含激素类），中药前处理及提取车间（口服制 剂、注射制剂）；3、广州市从化明 ...